Trial Profile

An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixoberogene soroparvovec (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions; First in man
Acronyms OPTIC
Sponsors Adverum Biotechnologies

Most Recent Events

18 Nov 2024 Results reporting new 4-year OPTIC long-term follow-up data presented in an Adverum Biotechnologies media release.
04 Nov 2024 According to an Adverum Biotechnologies media release, 4-year OPTIC data anticipated in Q4 2024
26 Sep 2023 According to an Adverum Biotechnologies media release, Presentation of OPTIC four-year Ixo-vec aflibercept protein expression data and three-year extension efficacy and safety data at the American Academy Ophthalmology (AAO) Meeting in November 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com